Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>Encompass Health, in their Second Quarter 2024 earnings report, exhibits both substantial growth and areas of watchful consideration for investors.</li>
<li>Foremost, Encompass Health reported a commendable 9.6% increase in revenue and an 8.9% rise in adjusted EBITDA, driven primarily by a 6.7% increase in total discharges, indicating strong business operations and market demand.</li>
<li>Notably, same-store discharge growth was marked at 4.8%, signaling robust internal growth.</li>
</ul>


Encompass Health, in their Second Quarter 2024 earnings report, exhibits both substantial growth and areas of watchful consideration for investors.
Foremost, Encompass Health reported a commendable 9.6% increase in revenue and an 8.9% rise in adjusted EBITDA, driven primarily by a 6.7% increase in total discharges, indicating strong business operations and market demand.
Notably, same-store discharge growth was marked at 4.8%, signaling robust internal growth.


Encompass Health Corporation: Enhanced Revenue Optimization Initiatives & Other Major Drivers

<ul>
<li>Encompass Health Corporation released its First Quarter 2024 earnings, showing a robust financial performance characterized by a 13.4% increase in revenue and a 19.2% rise in adjusted EBITDA.</li>
<li>This performance has prompted the company to raise its full-year 2024 guidance, signaling a positive outlook based on the quarter's results.</li>
<li>The growth was primarily driven by an increase in total discharges and strategic initiatives, including the expansion into de novo hospitals and addition of inpatient beds.</li>
</ul>


Encompass Health Corporation released its First Quarter 2024 earnings, showing a robust financial performance characterized by a 13.4% increase in revenue and a 19.2% rise in adjusted EBITDA.
This performance has prompted the company to raise its full-year 2024 guidance, signaling a positive outlook based on the quarter's results.
The growth was primarily driven by an increase in total discharges and strategic initiatives, including the expansion into de novo hospitals and addition of inpatient beds.


Encompass Health Corporation: A Tale Of Revenue Growth and Market Expansion!

<ul>
<li>Encompass Health's earnings for the fourth quarter of 2023 revealed yet another strong showing for the company, capping off a robust year of performance.</li>
<li>On the positive side, a significant growth in both volume and revenue was reported for the year.</li>
<li>The company recorded a 10.4% increase in revenue, driven by an 8.7% spike in total discharges, indicating its value proposition indeed resonates with referral sources, payers, and the patients it serves.</li>
</ul>


Encompass Health's earnings for the fourth quarter of 2023 revealed yet another strong showing for the company, capping off a robust year of performance.
On the positive side, a significant growth in both volume and revenue was reported for the year.
The company recorded a 10.4% increase in revenue, driven by an 8.7% spike in total discharges, indicating its value proposition indeed resonates with referral sources, payers, and the patients it serves.


Encompass Health Corporation: 4 Pivotal Factors That Are Shaping Its Growth Journey!

United States

Encompass Health Corporation provides inpatient rehabilitative healthcare services.  The Company operates inpatient rehabilitation hospitals, outpatient and rehabilitation satellites, and home health agencies. Encompass Health provides treatment on both an inpatient and outpatient basis.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Encompass Health (EHC US)

Encompass Health Corporation: Enhanced Revenue Optimization Initiatives & Other Major Drivers

Encompass Health, in their Second Quarter 2024 earnings report, exhibits both substantial growth and areas of watchful consideration for investors.

Baptista Research

Encompass Health Corporation: A Tale Of Revenue Growth and Market Expansion!

Encompass Health Corporation released its First Quarter 2024 earnings, showing a robust financial performance characterized by a 13.4% increase in...

Baptista Research

Encompass Health Corporation: 4 Pivotal Factors That Are Shaping Its Growth Journey!

Encompass Health's earnings for the fourth quarter of 2023 revealed yet another strong showing for the company, capping off a robust year of...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)